Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Finch Therapeutics Group (FNCH)
OTHER OTC:FNCH
Holding FNCH?
Track your performance easily
FNCH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.80 - $14.26
Previous Close$11
Volume457.00
Average Volume (3M)4.30K
Market Cap
$16.70M
Enterprise Value$29.65M
Total Cash (Recent Filing)$16.04M
Total Debt (Recent Filing)$28.99M
Price to Earnings (P/E)―
Beta3.11
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.82
Shares Outstanding1,605,763
10 Day Avg. Volume2,578
30 Day Avg. Volume4,303
Standard Deviation1.04
R-Squared0.00342
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)15.94
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.78
Enterprise Value/Gross Profit277.14
Enterprise Value/Ebitda-1.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Finch Therapeutics Group News
PremiumCompany Announcements
Finch Therapeutics Group to Delist from Nasdaq
PremiumCompany Announcements
Finch Therapeutics Faces Nasdaq Delisting and Patent Litigation
Ownership Overview
12.62% Insiders
0.47% Mutual Funds
1.32% Other Institutional Investors
85.59% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
FNCH FAQ
What was Finch Therapeutics Group’s price range in the past 12 months?
Finch Therapeutics Group lowest stock price was $0.80 and its highest was $14.26 in the past 12 months.
What is Finch Therapeutics Group’s market cap?
Currently, no data Available
When is Finch Therapeutics Group’s upcoming earnings report date?
Finch Therapeutics Group’s upcoming earnings report date is May 09, 2024 which is 227 days ago.
How were Finch Therapeutics Group’s earnings last quarter?
Finch Therapeutics Group released its earnings results on Mar 28, 2024. The company reported -$1.894 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.894.
Is Finch Therapeutics Group overvalued?
According to Wall Street analysts Finch Therapeutics Group’s price is currently Overvalued.
Does Finch Therapeutics Group pay dividends?
Finch Therapeutics Group does not currently pay dividends.
What is Finch Therapeutics Group’s EPS estimate?
Finch Therapeutics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Finch Therapeutics Group have?
Finch Therapeutics Group has 1,605,763 shares outstanding.
What happened to Finch Therapeutics Group’s price movement after its last earnings report?
Finch Therapeutics Group reported an EPS of -$1.894 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.245%.
Which hedge fund is a major shareholder of Finch Therapeutics Group?
Among the largest hedge funds holding Finch Therapeutics Group’s share is Baupost Group LLC. It holds Finch Therapeutics Group’s shares valued at N/A.
---
Finch Therapeutics Group Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
270.37%
12-Months-Change
Fundamentals
Return on Equity
-67.28%
Trailing 12-Months
Asset Growth
-31.83%
Trailing 12-Months
Company Description
Finch Therapeutics Group
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
---
Technical Analysis
---